GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (FRA:DV3R) » Definitions » EV-to-FCF

Delcath Systems (FRA:DV3R) EV-to-FCF : -4.25 (As of May. 05, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Delcath Systems EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Delcath Systems's Enterprise Value is €123.22 Mil. Delcath Systems's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-28.97 Mil. Therefore, Delcath Systems's EV-to-FCF for today is -4.25.

The historical rank and industry rank for Delcath Systems's EV-to-FCF or its related term are showing as below:

FRA:DV3R' s EV-to-FCF Range Over the Past 10 Years
Min: -934.95   Med: -1.7   Max: 0.49
Current: -4.23

During the past 13 years, the highest EV-to-FCF of Delcath Systems was 0.49. The lowest was -934.95. And the median was -1.70.

FRA:DV3R's EV-to-FCF is ranked worse than
100% of 364 companies
in the Medical Devices & Instruments industry
Industry Median: 28.38 vs FRA:DV3R: -4.23

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Delcath Systems's stock price is €5.00. Delcath Systems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.625. Therefore, Delcath Systems's PE Ratio for today is At Loss.


Delcath Systems EV-to-FCF Historical Data

The historical data trend for Delcath Systems's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems EV-to-FCF Chart

Delcath Systems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 -3.46 -2.40 -1.76 -2.31

Delcath Systems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.76 -1.89 -3.18 -1.62 -2.31

Competitive Comparison of Delcath Systems's EV-to-FCF

For the Medical Devices subindustry, Delcath Systems's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Delcath Systems's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Delcath Systems's EV-to-FCF falls into.



Delcath Systems EV-to-FCF Calculation

Delcath Systems's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=123.224/-28.971
=-4.25

Delcath Systems's current Enterprise Value is €123.22 Mil.
Delcath Systems's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-28.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Delcath Systems  (FRA:DV3R) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Delcath Systems's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.00/-2.625
=At Loss

Delcath Systems's share price for today is €5.00.
Delcath Systems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.625.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Delcath Systems EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Delcath Systems's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Delcath Systems (FRA:DV3R) Business Description

Traded in Other Exchanges
Address
1633 Broadway, Suite 22C, New York, NY, USA, 10019
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems (FRA:DV3R) Headlines

No Headlines